“PRECISION aims to enable patients and clinicians to make informed, biology-based decisions to avoid unnecessary and burdensome treatment of indolent DCIS. The answer can only be found by synergistic collaboration between leading scientists, clinicians and patient advocates.
There is a wide spectrum of DCIS ranging from low to high risk. “Low-risk” means it is more likely to be harmless and not progress to invasive breast cancer. “Low-risk” includes low and intermediate grades (1 and 2), as well as other physical and biological features which have a low potential for progression to a future invasive cancer. “Low-risk” DCIS differs greatly from “high-risk” DCIS which some research has shown to be faster growing and more closely associated with a future invasive breast cancer.”
Click the link below to read about this “Grand Challenge” project as well as the important role of Patient Advocates:
DCIS 411 